Artemether/Lumefantrine
ApprovedSmall molecule
Merck & Co.Artemether/Lumefantrine is one of 83 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Approved.
3
Indications
15
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Artemether/Lumefantrine
Merck & Co.Approved
Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Malaria9 trials
Show 6 more trials
Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
Terminated·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 4·NCT01728961·19 enrolled
Interaction2 trials
Treatment1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Artemether/Lumefantrine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company